Status:

TERMINATED

Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study

Lead Sponsor:

Medco Health Solutions, Inc.

Conditions:

Cardiovascular Disease

Eligibility:

All Genders

18-75 years

Brief Summary

The primary objective of this trial is to demonstrate the non-inferiority of clopidogrel compared to prasugrel over 6 months in cardiovascular disease patients when the clopidogrel cohort is limited t...

Detailed Description

This is a prospective, non-randomized, open-label, non-inferiority comparative effectiveness outcomes trial comparing clopidogrel EMs (confirmed by CYP2C19 genotype)and receiving clopidogrel at 75 mg/...

Eligibility Criteria

Inclusion

  • Men and women between 18 years and 75 years of age
  • Recent prescription for clopidogrel or prasugrel.
  • Participant is willing and able to provide informed consent.

Exclusion

  • Previous use of any thienopyridine within 4 months of initiating new clopidogrel or prasugrel therapy.
  • Participant refusal to participate in the study.
  • Anticipated discontinuation of clopidogrel or prasugrel within the 6 month study follow-up period
  • Participants that have previously stated "do not contact"

Key Trial Info

Start Date :

October 1 2009

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

May 1 2012

Estimated Enrollment :

4471 Patients enrolled

Trial Details

Trial ID

NCT00995514

Start Date

October 1 2009

End Date

May 1 2012

Last Update

May 30 2012

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Medco Health Solutions, Inc

Franklin Lakes, New Jersey, United States, 07417

Genotype Guided Comparison of Clopidogrel and Prasugrel Outcomes Study | DecenTrialz